Apoptotic cell death in disease—Current understanding of the NCCD 2023
I Vitale, F Pietrocola, E Guilbaud… - Cell Death & …, 2023 - nature.com
Apoptosis is a form of regulated cell death (RCD) that involves proteases of the caspase
family. Pharmacological and genetic strategies that experimentally inhibit or delay apoptosis …
family. Pharmacological and genetic strategies that experimentally inhibit or delay apoptosis …
Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures
M Hallek, O Al‐Sawaf - American journal of hematology, 2021 - Wiley Online Library
Disease overview Chronic lymphocytic leukemia (CLL) is one of the most frequent types of
leukemia. It typically occurs in elderly patients and has a highly variable clinical course …
leukemia. It typically occurs in elderly patients and has a highly variable clinical course …
First-line venetoclax combinations in chronic lymphocytic leukemia
B Eichhorst, CU Niemann, AP Kater… - … England Journal of …, 2023 - Mass Medical Soc
Background Randomized trials of venetoclax plus anti-CD20 antibodies as first-line
treatment in fit patients (ie, those with a low burden of coexisting conditions) with advanced …
treatment in fit patients (ie, those with a low burden of coexisting conditions) with advanced …
[HTML][HTML] Pirtobrutinib after a covalent BTK inhibitor in chronic lymphocytic leukemia
Background Patients with chronic lymphocytic leukemia (CLL) or small lymphocytic
lymphoma (SLL) have poor outcomes after the failure of covalent Bruton's tyrosine kinase …
lymphoma (SLL) have poor outcomes after the failure of covalent Bruton's tyrosine kinase …
Targeting apoptosis in cancer therapy
BA Carneiro, WS El-Deiry - Nature reviews Clinical oncology, 2020 - nature.com
For over three decades, a mainstay and goal of clinical oncology has been the development
of therapies promoting the effective elimination of cancer cells by apoptosis. This …
of therapies promoting the effective elimination of cancer cells by apoptosis. This …
Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial
AH Wei, P Montesinos, V Ivanov… - Blood, The Journal …, 2020 - ashpublications.org
Effective treatment options are limited for patients with acute myeloid leukemia (AML) who
cannot tolerate intensive chemotherapy. Adults age≥ 18 years with newly diagnosed AML …
cannot tolerate intensive chemotherapy. Adults age≥ 18 years with newly diagnosed AML …
Programming inflammatory cell death for therapy
S Christgen, RE Tweedell, TD Kanneganti - Pharmacology & therapeutics, 2022 - Elsevier
Programmed cell death (PCD) is an essential part of organismal development and plays
fundamental roles in host defense against pathogens and the maintenance of homeostasis …
fundamental roles in host defense against pathogens and the maintenance of homeostasis …
ASCEND: phase III, randomized trial of acalabrutinib versus idelalisib plus rituximab or bendamustine plus rituximab in relapsed or refractory chronic lymphocytic …
P Ghia, A Pluta, M Wach, D Lysak, T Kozak… - Journal of Clinical …, 2020 - ascopubs.org
PURPOSE Acalabrutinib, a highly selective, potent, Bruton tyrosine kinase inhibitor, was
evaluated in this global, multicenter, randomized, open-label, phase III study in patients with …
evaluated in this global, multicenter, randomized, open-label, phase III study in patients with …
Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia: results from a phase Ib/II study
AH Wei, SA Strickland Jr, JZ Hou, W Fiedler… - Journal of Clinical …, 2019 - ascopubs.org
PURPOSE Effective treatment options are limited for patients with acute myeloid leukemia
(AML) who cannot tolerate intensive chemotherapy. An international phase Ib/II study …
(AML) who cannot tolerate intensive chemotherapy. An international phase Ib/II study …
Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab
JF Seymour, TJ Kipps, BF Eichhorst… - Blood, The Journal …, 2022 - ashpublications.org
Abstract The MURANO trial (A Study to Evaluate the Benefit of Venetoclax Plus Rituximab
Compared With Bendamustine Plus Rituximab in Participants With Relapsed or Refractory …
Compared With Bendamustine Plus Rituximab in Participants With Relapsed or Refractory …